Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jw Therapeutics Co. Ltd.
Headquarters: Shanghai, China
Website: https://www.jwtherapeutics....
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: MIn Liu, MBA
Number Of Employees: 398
Enterprise Value: $22,219,016
PE Ratio: -1.17
Exchange/Ticker 1: HKEX:2126
Exchange/Ticker 2: N/A
Latest Market Cap: $102,063,007
BioCentury | Dec 17, 2024
Management Tracks
Bruce Cozadd to retire as Jazz’s CEO
Plus: James Li named venture partner at Frazier, and updates from Crinetics, NeoPhore, VectorY and more
BioCentury | Jul 31, 2024
Management Tracks
Min Liu succeeds Yiping Li as CEO of JW
Plus: John Chin to retire as CBO from Antengene, and updates from ADARx, bit bio and Santhera
BioCentury | Jun 17, 2024
Product Development
Autoimmune CAR Ts: Is CD19 enough?
Presentations from iCell, JW and others at EULAR provide new insight into autoimmune CAR T mechanisms
BioCentury | Dec 19, 2023
Management Tracks
Xin Fu named CFO at InnoCare
Plus: Mahjoubi resigns as CEO of Innate, and updates from Viatris, Vicore,
BioCentury | Sep 30, 2023
Product Development
CAR T’s next act: autoimmune diseases
CAR T developers exploring technologies and development paths to take the disruptive modality into new applications
BioCentury | Sep 13, 2023
Management Tracks
CEO Nick Leschly shifting to chair as 2seventy bio restructures
Plus: CFO Galá promoted at Jazz, and updates from Geron, Mirum, ReNAgade,
BioCentury | Sep 9, 2023
Deals
CAR T collaborations: the next cross-border deal trend?
BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development
BioCentury | Mar 21, 2023
Management Tracks
Debra Yu joins Panacea as partner, COO
Plus: Sonata hires Kite veteran Marincola as CSO and updates from Ascidian, Olink, Azafaros, Akoya and more
BioCentury | Feb 4, 2023
Market Access
Rare diseases, MNCs grow presence on China’s NRDL
Even with big price reductions, China’s national reimbursement list is a lure for drug developers around the globe
BioCentury | Mar 1, 2022
Product Development
Legend’s target strategy pays off with BCMA CAR T approval
How Legend and Janssen gained the first FDA approval of a Chinese CAR T and what’s next for Legend’s pipeline
Items per page:
1 - 10 of 23